TY  - JOUR
AU  - Di Cosimo, Serena
AU  - Pérez-García, José Manuel
AU  - Bellet, Meritxell
AU  - Dalenc, Florence
AU  - Gil Gil, Miguel J
AU  - Ruiz Borrego, Manuel
AU  - Gavilá, Joaquín
AU  - Sampayo-Cordero, Miguel
AU  - Aguirre, Elena
AU  - Schmid, Peter
AU  - Marmé, Frederik
AU  - Gligorov, Joseph
AU  - Schneeweiss, Andreas
AU  - Albanell, Joan
AU  - Zamora, Pilar
AU  - Wheatley, Duncan
AU  - Martínez-De Dueñas, Eduardo
AU  - Carañana, Vicente
AU  - Amillano, Kepa
AU  - Mina, Leonardo
AU  - Malfettone, Andrea
AU  - Cortés, Javier
AU  - Llombart-Cussac, Antonio
PY  - 2023
DO  - 10.1093/oncolo/oyac205
UR  - http://hdl.handle.net/10668/19828
T2  - The oncologist
AB  - Palbociclib has gained a central role in the treatment of hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC). Despite its manageable toxicity profile, venous thromboembolism (VTE) or...
LA  - en
KW  - advanced breast cancer
KW  - endocrine therapy
KW  - interstitial lung disease
KW  - neutropenia
KW  - palbociclib
KW  - pneumonitis
KW  - venous thromboembolism
KW  - Female
KW  - Humans
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Breast Neoplasms
KW  - Fulvestrant
KW  - Letrozole
KW  - Pulmonary Embolism
KW  - Receptor, ErbB-2
KW  - Receptors, Estrogen
KW  - Venous Thromboembolism
TI  - Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial.
TY  - research article
VL  - 28
ER  -